Finerenone Improves Albuminuria via MR-TRPC Signaling in Diabetic Kidney Disease
Finerenone is associated with reductions in albuminuria in diabetic kidney disease, together with improvements in podocyte injury indices and glomerular hemodynamics. These benefits may be mediated in part through MR-TRPC5 signaling although additional pathways are likely to contribute.
Authors
- Kengo Kidokoro (ORCID: https://orcid.org/0000-0002-4932-0166)
- Eriko Kajimoto
- Rie Tatsugawa
- Hajime Nagasu
- Tsukasa Iwakura
- David Z.I. Cherney (ORCID: https://orcid.org/0000-0003-4164-0429)
- Masanobu Takasu (ORCID: https://orcid.org/0009-0006-9201-075X)
- Hiroyuki Kadoya (ORCID: https://orcid.org/0000-0002-3868-3869)
- Tamaki Sasaki
- Akira Hirano (ORCID: https://orcid.org/0000-0002-4769-0593)
- Yoshihisa Wada
- Seiji Kishi
- Naoki Kashihara
- Masafumi Wada
Institutions
- University Health Network (CA)
- Kawasaki Medical School (JP)
Publication Details
- Journal
- Hypertension
- Published
- 2026-01-22
- DOI
- https://doi.org/10.1161/hypertensionaha.125.25739
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00